Correlations between anti-CCP and patient’s age and age at disease onset.

<p>Anti-CCP correlated with the age of patients (A) and age at disease onset (C). Anti-CCP studied according to patient’s age (B) and age at disease onset (D).</p

Distribution of MBL levels in different <i>MBL2</i> haplotypes and diplotypes.

<p><i>MBL2</i> diplotypes were reconstructed from promoter variant −221X/Y and variants in exon1 (Codon 52+54+57, A/O) and divided into high MBL producers (<i>YA/YA</i>), intermediate (<i>YA/YO</i>, <i>XA/XA</i> and <i>XA/YA</i>) and low MBL producers (<i>YO/YO</i>, <i>XA/YO</i>). Serum MBL levels were segregated according to different <i>MBL2</i> diplotypes in patients and relatives (A), and different <i>MBL2 </i>secretor haplotypes in RA patients (B) and relatives (C).</p

Clinical and demographic features of the RA patients, relatives and healthy controls.

<p>Anti-CCP: anti-cyclic citrullinated peptide antibody, (^a): Total of samples with available data are 154; (^b): Total samples with available data are 74.</p><p>NS: Not significant; NA: not available; ND: not determined. Values expressed in medians and interquartiles range.</p

Distribution of MBL levels in different <i>MBL2</i> genotypes.

<p>Serum MBL levels according to different genotypes of studied <i>MBL2</i> variants in RA patients (A) and relatives (B).</p

Distribution of MBL levels in studied Brazilian cohort.

<p>Distribution of MBL levels in patients, relatives and controls (A), according to different functional classes (B), according to age at disease onset (C) and according to disease duration (D). Open circles indicate possible outliers in each group and the *represents significant distribution amongst the investigated groups.</p

Distribution of observed MBL2 haplotype in RA patients, relatives and healthy controls.

<p>NS: not significant; NA: not applicable.</p>#<p>P values were calculated by logistic regression adjusted for age, gender and ethnicity.</p

Distribution of MBL levels in RA patients segregated by clinical parameters.

<p>Distribution of MBL levels according to presence of nodules (A), Secondary Sjögren’s syndrome (B), positivity for anti-CCP (C) and positivity for Rheumatoid factor (D).</p

Investigated SNP variants in leprosy patients and controls.

<p>Investigated SNP variants in leprosy patients and controls.</p

Distribution of investigated RIPK2 haplotypes in clinically classified leprosy patients and controls.

<p>Distribution of investigated RIPK2 haplotypes in clinically classified leprosy patients and controls.</p

Distribution of investigated <i>NOD2</i>, <i>RIPK2</i>, and <i>LRRK2</i> variants in clinically classified leprosy patients and controls.

<p>Distribution of investigated <i>NOD2</i>, <i>RIPK2</i>, and <i>LRRK2</i> variants in clinically classified leprosy patients and controls.</p